Business excellence models: limitations, reflections and further development

Models of Excellence: Improving Oncology Drug Development

Simulations based on disease-progression models and phase II trial results can predict phase III results and have the potential to improve oncology drug development by informing end-of-phase II decisions (EOP2Ds). Many barriers impede effective use of modeling and simulation (M&S) for EOP2Ds in oncology: concerns about model validity, lack of access to M&S results and patient-level data, limite...

Further reflections on TREC

The paper reviews the TREC Programme up to TREC-6 (1997), considering the test results, the substantive ®ndings for IR that follow and the lessons TREC o€ers for IR evaluation. The paper focuses on the ad hoc retrieval task, with discussion of other test tracks as appropriate. The paper summarises the structure of the TREC work and analyses the experimental data in some detail. The analysis of ...

Conceptualization of business excellence model with a grand theory approach

This study aims to conceptualize business excellence model and identify its variables and indicators. The philosophical foundations of the pragmatic, humanistic theory of symbolic interactionism has been, quietly and the strategy of grand theory deal with open, axial and selective coding; whose output is a new concept. Data collection is based on documentation studies on excellence models. The ...

ISO 9000 and TQM for Business Excellence

There has been a major emphasis for manufacturing firms in Australia and New Zealand to seek certification to the International Quality Standards ISO 9000. These have been rapidly accepted as a standard for documenting processes and procedures. ISO 9000 is a process that typically shifts an organisation’s culture to allow successful Total Quality Management (TQM) implementation. Researchers fou...

Further Reflections on the Guillotine